常用抗骨质疏松药物对脊柱融合影响的研究进展

被引：9

作者：

王雪鹏 ^{[1
,2
]}

朱六龙 ^{[1
,2
]}

田纪伟 ^{[3
]}

机构：

[1] 杭州市第一人民医院骨科

[2] 南京医科大学附属杭州医院骨科

[3] 上海交通大学附属第一人民医院脊柱外科

来源：

中国脊柱脊髓杂志 | 2015年 / 25卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

摘要：

<正>骨质疏松症(osteoporosis,OP)是一种以骨量减低、骨微结构破坏为特征,导致骨脆性增加和容易骨折的全身性疾病。脊柱融合内固定是治疗脊柱退变性疾病的金标准[1]。大量临床观察证实腰椎间盘突出症、腰椎管狭窄症以至腰椎退变性侧凸等患者都可能会伴有椎体骨质疏松[2]。骨质疏松症病理状态不利于骨折愈合,椎体疏松也不利于内固定机械稳定的维持,但骨质疏松症并不是脊柱融合术的禁忌证[3]。不同的抗骨质疏松药物对参与骨重建的成骨细胞、

引用

页码：946 / 949

页数：4

共 22 条

[1]

Selective estrogen receptor modulators (SERMs): A review of clinical data [J].

Mirkin, Sebastian ;

Pickar, James H. .

MATURITAS, 2015, 80 (01) :52-57

[2]

Non-Union Rate With Stand-Alone Lateral Lumbar Interbody Fusion [J].

Watkins, Robert ;

Watkins, Robert, III ;

Hanna, Robert .

MEDICINE, 2014, 93 (29) :e275

[3]

Intermittent administration of teriparatide enhances graft bone healing and accelerates spinal fusion in rats with glucocorticoid-induced osteoporosis [J].

Sugiura, Tsuyoshi ;

Kashii, Masafumi ;

Matsuo, Yohei ;

Morimoto, Tokimitsu ;

Honda, Hirotsugu ;

Kaito, Takashi ;

Iwasaki, Motoki ;

Yoshikawa, Hideki .

SPINE JOURNAL, 2015, 15 (02) :298-306

[4]

The role of vitamin D in human fracture healing: a systematic review of the literature.[J].Erwin A. Gorter;Neveen A.T. Hamdy;Natasha M. Appelman-Dijkstra;Inger B. Schipper.Bone.2014,

[5]

Effect of Intermittent Administration of Teriparatide (Parathyroid Hormone 1–34) on Bone Morphogenetic Protein-Induced Bone Formation in a Rat Model of Spinal Fusion.[J].Tokimitsu Morimoto;Takashi Kaito;Masafumi Kashii;Motoki Iwasaki;Hideki Yoshikawa.Journal of Bone and Joint Surgery.2014, 13

[6]

Zoledronic acid infusion for lumbar interbody fusion in osteoporosis.[J].Chao-Wei Tu;Kuo-Feng Huang;Hsien-Ta Hsu;Hung-Yi Li;Stephen Shei-Dei Yang;Yi-Chu Chen.Journal of Surgical Research.2014,

[7]

Effect of intermittent PTH (1–34) on posterolateral spinal fusion with iliac crest bone graft in an ovariectomized rat model.[J].Z. Qiu;L. Wei;J. Liu;K. R. Sochacki;X. Liu;C. Bishop;M. Ebraheim;H. Yang.Osteoporosis International.2013, 10

[8]

Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis [J].